INDEX TO VOLUME 5

AUTHOR INDEX

AARONSON, D.E., 497
AHMED, U., 269
AMANO, Y., 357
ANDERSON, G.G., 303
AZNAR-RAMOS, R., 187
BARTHOLOMEW, W.R., 85
BEHRMAN, S.J., 357
BERGSTRÖM, S., 215
BERISTAIN, I., 279
BERNSTEIN, G.S., 369
BO, W.J., 319
BORIS, A., 57, 489
BRADLEY, E.M., 31
CALDERON, J.J., 177
CALDWELL, B.V., 303
CERVANTES, A., 279
COUTINHO, E.M., 389, 395
CUTLER, J.C., 401
DAVIS, J.E., 269
DE SOUZA, J.C., 395
DiPASQUALE, G., 39
EGG, D., 515
EL-MAHGOUB, S., 21
ENDERS, R.G., 85
ESPINOZA, C., 203
FERIA-VELASCO, A., 187
FILHO, J.A., 389
FUCHS, F., 119
GHANEM, M.H., 105
GOLDZIEHER, J.W., 31, 177
GONZÁLES-ANGULO, A., 187
GORDOVSKY, J., 457
GUERGIS, F.K., 105
GUILLERMIN, R., 1
HOBBINS, J.C., 303
JOHANSSON, E.D.B., 445
JOHNSON, D.S., 155, 237, 327
JOSHI, U.M., 53
KARIM, M., 21
KESSLER, A., 423
KOTHARE, U.R., 147
KRUEGER, W.A., 319
KUDZMA, D.J., 31
LIPPES, J., 85
LJUNGKVIST, I., 473
LOEWIT, K., 515
LÖÖF, L., 313
MAQUEO, M., 177
MATTOS, C.E.R., 389
McDOUGALL, E., 39
MEDEL, M., 203
MEYER, R.K., 413
MOYER, D.L., 497
NELSON, E.W., JR., 57, 489
NILSSON, O., 313
NYGREN, K.C., 445
OSMAN, M.M., 105
PEÑA, A., 457
PERKIN, G.W., 423
PRAGAY, D.A., 85
PRAGER, R., 203
RANGNEKAR, K.N., 53
RAO, J.M., 295
RAO, S.S., 53
RASSAERT, C.L., 39
REDDY, P.R.K., 295
RICCABONA, G., 515
RICE-WRAY, E., 177, 279, 457
RISK, A., 119
SANT'ANNA, A.R.S., 389

SEWARD, P., 369
SHAHANI, S.M., 147
SHAW, S.T., JR., 497
SHULMAN, S., 269
SILVA, M.C., 389
SINGH, B., 401
SPEROFF, L., 303
STANDLEY, C.C., 423
STONE, S.C., 129
TATUM, H.J., 389
TERENIUS, L., 473
THORNEYCROFT, I.H., 129
TOPPOZADA, H.K., 105
TRIPP, L., 39
TRMAL, T., 57, 489
UTIDJIAN, H.M.D., 401
WIDE, L., 445
YING, S.Y., 413
ZAMBELIS, N., 515
ZAPPI, E., 269
ZIPPER, J., 203

INDEX TO VOLUME 5

SUBJECT INDEX

Abortifacient, anti-placental serum (monkey), 357
Abortion, intravenous prostaglandin $F_{2\alpha}$, 303
Alkaline hematin method, quantitation of menstrual blood loss, 497
Analysis and collection, human fallopian tubal fluid, 85
Androgenic-myotrophic steroids, anti-ovulatory effect (rat), 489
Antagonist of estradiol-17β, action (rat), 39
Antibodies to tetanus toxoid after Ovulen therapy (mouse), 53
Antiestrogens, facilitation of ovulation (rat), 413
Antifertility action, reversible, testosterone propionate in human males, 295
Antifertility agents, suppression of attachment reaction (rat), 473
Antifertility compounds, interference with blastocyst implantation (mouse), 215
Antigon-F, intrauterine contraceptive device, 119
Antiimplantation effect, polyethylene IUD (rat), 319
Anti-ovulatory effect, androgenic-myotrophic steroids (rat), 489
Anti-placental serum, abortifacient (monkey), 357
Attachment reaction, suppression by antifertility agents (rat), 473
Balance study, metabolic, effect of oral steroid contraceptive, 31
Blastocyst implantation, interference by antifertility compounds (mouse), 215
Body composition, effect of oral steroid contraceptive, 31
Candida albicans, effect by vaginal preparations and contraceptives, 401
Chemical approach, termination of pregnancy, 237
Chemistry and physiology, hypothalamic releasing factors for gonadotropins, 1
Chlormadinone acetate, daily, 369
Clinic operation, termination of pregnancy, 237
Collection and analysis, human fallopian tubal fluid, 85
Contraceptive agents, ovarian morphology, 177
Contraceptive effect of iron (rat), 515
Copper, IUFB effect on uterine motility (rabbit), 203
Endometrium, ultrastructural changes after megestrol acetate, 187
Estradiol hexa-hydro-benzoate and norgestrel, injectable contraceptive, 395
Estradiol-17β antagonist action (rat), 39
17 Ethinyl, 4 estrone, 17β-ol-3-one 17β enanthate (norethisterone enanthate)
17-Ethinyl-19-nortestosterone (norethindrone)
Ethinyl estradiol-norethisterone acetate, effect on serum lipids, 105
DL-13β, Ethyl-17α-ethynyl-17β hydroxygon-4-en-3-one (norgestrel)
d-13-Ethyl-17α-17β-hydroxy-4-gonene-3-one (d-norgestrel)
Ethynylestradiol-norgestrel, metabolic balance study, 31

Female sterilization, prognosis for simplified outpatient procedures, 155
Fluid from IUD-containing horn, changes in uterine epithelium (mouse), 313
Genital infections, prophylaxis by vaginal contraceptive, 401
Gonadotropins, hypothalamic releasing factors, 1
Human fallopian tubal fluid, collection and analysis, 85
Human reproduction, WHO expanded research programme, 423
Humoral antibodies to tetanus toxoid, after Ovulen therapy (mouse), 53
Hypothalamic releasing factors for gonadotropins, physiology and chemistry, 1
Imaging techniques, outpatient, female sterilization, 155
Immunologic consequences of vasectomy, 269
Implantation interference by antifertility compounds (mouse), 215
Injectable contraceptive, norgestrel and estradiol hexa-hydro-benzoate, 395
Injectable norethisterone enanthate, long-term use, 21
Iron, evaluation of vaginal application (rat), 515
IUCD (see also IUD and IUFB), 119
    Antigon-F, 119
IUD (see also IUCD and IUFB), 147
    (rat), 319
    polyethylene, antiimplantation effect (rat), 319
    vaginal smears, 147
IUD-containing horn, fluid influencing changes in uterine epithelium (mouse), 313
IUFB (see also IUCD and IUD), 203
    copper, zinc and polyethylene on uterine motility (rabbit), 203
Lipids, serum, effect of norethisterone acetate-ethinyl estradiol, 105
Long-term contraception, silastic capsules, megestrol acetate, 389
Long-term IUD use, vaginal smears, 147
Long-term use, injectable norethisterone enanthate, 21
Lynestrenol-mestranol, modified sequential contraceptive, 457
Male sterilization, current status and future directions, 327
Materials technology, male sterilization, 327
Megestrol acetate
    subcutaneous silastic capsules, 389
    ultrastructural changes in endometrium, 187
Menstrual blood loss, quantitation by alkaline hematin method, 497
Mestranol-lynestrenol (7 + 15), modified sequential contraceptive, 457
Metabolic balance study, effect of oral steroid contraceptive, 31
Micro-dose d-norgestrel, clinical study, 279
Morphology, ovarian, steroid contraceptive agents, 177
Myotrophic-androgenic steroids, anti-ovulatory effect (rat), 489
Non-surgical sterilization procedures, outpatient, female sterilization, 155
Norethindrone (17-ethinyl-19-nortestosterone), 445
    postovulatory contraception, 445
Norethisterone acetate-ethinyl estradiol, effect on serum lipids, 105

Norethisterone enanthate (17 ethinyl, 4 estrone, 17β-ol-3-one 17β enanthate), 21
    injectable, long-term use, 21
Norgestrel (DL-13β, ethyl-17α-ethynyl-17β hydroxygon-4-en-3-one), 395
d-Norgestrel (d-13-ethyl-17α-17β-hydroxy-4-gonene-3-one), 279
    continuous daily micro-dose, clinical study, 279
Norgestrel-ethynylestradiol, metabolic balance study, 31
Norgestrel and estradiol hexa-hydro-benzoate, injectable contraceptive, 395
Oral contraceptive
    daily chlormadinone acetate, 369
    effect on serum lipids, 105
Oral contraceptive steroids, radioimmunoassay of serum progesterone, 129
Oral steroid contraceptive, effect on weight and body composition, 31
Outpatient procedures, female sterilization, 155
Ovarian morphology, prolonged use of steroid contraceptive agents, 177
Ovulation
    facilitation with antiestrogens (rat), 413
    pubertal, effects of progestational steroids (rat), 57
Ovulen, effect on humoral antibodies to tetanus toxoid (mouse), 53
Physical approach, termination of pregnancy, 237
Physiology and chemistry, hypothalamic releasing factors for gonadotropins, 1
Polyethylene
    IUD, antiimplantation effect (rat), 319
    IUFB effect on uterine motility (rabbit), 203
Postovulatory contraception, norethindrone, 445
Practitioner training, termination of pregnancy, 237
Pre-aspiration procedures, termination of pregnancy, 237
Pregnancy termination, current status and future directions, 237
Pregnant mare serum (PMS) primed rats, facilitation of ovulation with antiestrogens, 413
Progestational steroids, effects on pubertal ovulation (rat), 57
Progesterone, serum, radioimmunoassay, 129
Progestogen contraceptive, d-norgestrel, clinical study, 279
Prostaglandin $F_{2\alpha}$, induction of therapeutic abortion, 303
Pubertal ovulation, effects of progestational steroids (rat), 57
Radioimmunoassay, serum progesterone, 129
Reabsorption, vaginally applied iron (rat), 515
Research and development, male sterilization, 327
Reversibility, male sterilization, 327
Reversible antifertility action, testosterone propionate in human males, 295
Reversible male sterilization, current status and future directions, 327
Sequential contraceptive, modified, mestranol-lynestrenol (7 + 15), 457
Serum lipids, effect of norethisterone acetate-ethinyl estradiol, 105
Silastic capsules, megestrol acetate, 389

Sterilization
female, conference summary, 155
male, conference summary, 327
Sterilization procedures, male sterilization, 327
Steroid contraceptive agents, ovarian morphology, 177
Subcutaneous silastic capsules, megestrol acetate, long-term contraception, 389
Surgical sterilization procedures, outpatient, female sterilization, 155
Termination of pregnancy, current status and future directions, 237
Testosterone propionate, reversible antifertility action in human males, 295
Tetanus toxoid, humoral antibodies after Ovulen therapy (mouse), 53
Therapeutic abortion, intravenous prostaglandin F_{2a}, 303
Trichomonas vaginalis, effect by vaginal preparations and contraceptives, 401
Ultrastructural changes in endometrium, megestrol acetate, 187
Ultrastructure of uterine epithelium, effect by fluid from IUD-containing horn (mouse), 313
Uterine epithelium, changes by fluid from IUD-containing horn (mouse), 313
Uterine luminal epithelium, effect of antifertility agents (rat), 473
Uterine motility, effect by IUFB (rabbit), 203
Vacuum aspiration, termination of pregnancy, 237
Vacuum requirements, termination of pregnancy, 237
Vacuum sources, termination of pregnancy, 237
Vaginal contraceptive
effect on Candida albicans and Trichomonas vaginalis, 401
prophylaxis against genital infection and contraception, 401
Vaginal iron, reabsorption (rat), 515
Vaginal smears, long-term IUD use, 147
Vasectomy, immunologic consequences, 269
Venereal disease, prophylaxis by vaginal contraceptive, 401
Weight, effect of oral steroid contraceptive, 31
WHO expanded research programme in human reproduction, 423
Zinc, IUFB effect on uterine motility (rabbit), 203